Aoxing Pharma has recently completed construction of chemical synthesis laboratories and pilot-manufacturing plant for the joint venture, which focuses on research, development, manufacturing and marketing of active pharmaceutical ingredients (API) of narcotics and neurological drugs for the China market.
The joint venture represents a new opportunity for both Aoxing Pharma and Johnson Matthey to expand their business in the rapidly growing pharmaceutical market in China.
Aoxing Pharma chairman and CEO Zhenjiang Yue said that they were very pleased with the progress that has been achieved by the joint venture that was created in April 2010 which paves the way for receiving GMP certification by the China SFDA by December 2010.
"We were pleased to recently welcome senior executives from Johnson Mattey to the newly renovated facility and look forward to starting chemical synthesis and manufacturing in 2011," Yue said.